CALL FOR POSTER ABSTRACTS *Due by Friday, February 12, 2016*

DIA/FDA Statistics 2016 Forum

APRIL 25–27, 2016
BETHESDA NORTH MARRIOTT HOTEL AND CONFERENCE CENTER
BETHESDA, MD

DIA



CALL FOR POSTER ABSTRACTS

POSTER SUBMISSION DETAILS AND GUIDELINES | SUBMISSION DEADLINE: FRIDAY, FEBRUARY 26, 2016

Poster Submission Overview and Topics:

The Program Committee welcomes abstract submissions for the Poster Session at the DIA Statistics 2016 Forum, April 25-27 in North Bethesda, MD.

This Call for Posters is for researchers in all fields related to statistics in life cycle management and regulatory review of pharmaceuticals, medical devices, and related health care products. The Poster Session is an opportunity to present your ideas to a diverse group of researchers who attend the DIA Statistics 2016 Forum encompassing statisticians, clinicians, academic and government researchers, fellows and professionals whose affiliation is consistent with the mission of DIA.

Poster topics can be about innovative quantitative approaches to improve efficiency of drug development, creative study designs, or new technology. They can also be about statistical methods to address existing challenges, or about approaches described in upcoming regulatory guidance. Posters about statisticians as leaders and collaborators in drug development are also encouraged.

General Submission Requirements

(Please read the following instructions carefully; incorrect or incomplete abstracts will not be considered.)

1. All abstracts must be submitted online to DIAglobal.org/Abstract.
2. Proposed abstract title must reflect the abstract content accurately and concisely.
3. All poster presentations must be noncommercial and scientific in nature and may not be used as a marketing opportunity. Any mention of specific products or and/or services must be limited to generic names, with no inclusion of brand names in any area of the poster, including poster titles and/or handouts. Logos and advertising may not appear anywhere on the poster.
4. Posters must be original in research and include appropriate empirical evidence.
5. Posters must include data, i.e., research results and conclusion for consideration.
6. Preliminary/pilot data is acceptable.
7. Abstracts submitted for presentation should not have been presented or published previously.

Onsite Requirements

- If an abstract is accepted, the primary author is required to pay the applicable registration fee, related expenses, and must be onsite at the forum during the designated poster session time. *Please note that an author may not represent more than one poster.*
- Co-authors who would like to be present for your session must register as well. If none of the authors are able to attend the forum, your poster must be withdrawn from the program.
- Presenters must organize and pay for all shipping arrangements for their poster materials. DIA will not ship or store any materials.
- Presenters must prepare a poster to fit a 4'× 8' poster board (four feet high and eight feet wide).

Eligibility

- Individuals eligible to submit a professional poster include post-doctoral scholars, medical residents, fellows and professionals whose affiliation is consistent with the mission of DIA.

Abstract Submission Deadline: Friday, February 26 2016

Notification: Week of March 14, 2016

Forum Dates: April 25-27

Poster Set Up: Monday, April 25 | Time to be announced

Poster Session: Tuesday, April 26 | 5:00-6:30 PM

Please submit all abstracts online at: DIAglobal.org/Abstract

Submit Your Abstract at **DIAglobal.org/Abstract**

REQUIRED DOCUMENTATION FOR ALL ABSTRACTS

- Participant Disclosure Information: all abstract authors must disclosure any relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices. If you are proposing an abstract on behalf of the author, as the submitter you will not be asked to disclose. However, should the abstract be accepted, the author will be informed that he/she must complete and submit a Participant Disclosure in order to participate in the program.
- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted abstracts will be available on DIA's website for attendee download.

SUBMISSION GUIDELINES *The following information will be requested at the time of submission.*

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. Do not wait until the last day.

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Submitter or Author Information

Prefix:
First Name:
Middle Name:
Last Name:
Name Suffix:
Degrees:
Job Title:
Company:
Country:
Address Line:
City:
State/Province:
Zip/Postal Code:
Phone:
Email:

NOTE: If you are submitting on behalf of author, you are considered the SUBMITTER and will need to complete the required information for yourself AND ALSO for the AUTHOR. Submitters will be the contact for author regarding the status of the abstract.

If you are submitting your own abstract, you are considered the AUTHOR and will be the direct contact for this abstract.

Abstract Title (maximum 125 characters, including spaces)
Titles should briefly describe the focus of the abstract as well as accurately reflect the content of the workshop.

Primary interest Area
Select the interest area that best relates to your abstract.

Keyword (Maximum 100 characters including spaces)
One or more key words are to be provided to highlight your abstract. Examples of key words: Personalized Medicine, Health Technology Assessment, Clinical Trial Agreements.

Objective (Maximum 300 characters including spaces)
Please provide a one sentence statement of the objective of the abstract.

Method (Maximum 300 characters including spaces)
When, where, and how was the study done? What materials were used or who was included in the study?

Results (Maximum 2000 characters including spaces)
What quantitative data was collected; what answer was found to the research question; what did the study find? Was the tested hypothesis true?

Conclusion (Maximum 2000 characters including spaces)
State what can be concluded from the study and its implications.

Abstracts will be reviewed, and authors will be notified of results the week of February 29, 2016

Submit Your Abstract at **DIAglobal.org/Abstract**